drugset / Trial / NCT05686096

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

NCT05686096

Phase 1 Completed 7 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the absorption, metabolism, excretion; and to evaluate the safety and tolerability of BMS-986435 in healthy male participants Participants will be admitted to the study site for 3 weeks.

Timeline

Start
2023-01-16
Primary completion
2023-04-08
Completion
2023-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject DELOCAMTEN Small molecule

Indications

No indication recorded.